HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Santhera Pharmaceuticals Holding AG

http://www.santhera.com

Latest From Santhera Pharmaceuticals Holding AG

Natural Beauty Big Leaguer L’Occitane Acquires No. 1 In British Luxury Skin Care

L’Occitaine’s $900m Elemis buy will build out the manufacturer/retailer’s premium, natural-oriented beauty portfolio, adding a prestige brand that aspires to be a leader in global skin care with its nature/science balance and cross-generational consumer appeal.

Beauty Deals

Vitamin Shoppe CEO Has Executive Experience In Cosmetics And Food Sectors

Sharon Leite has been Godiva Chocolatier president in North America since October 2017 will begin as Vitamin Shoppe CEO on Aug. 27. The firm agreed to part ways with former CEO Colin Watts in February after it reported 2017 net sales down 8.5% to $1.2bn for a net loss of $252.2m and $10.90 per share.

Advertising, Marketing & Sales Business Strategies

Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership

Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab returned its rights, and following Boehringers cancellation of a major-licensing deal in 2016. ZAI's decision may reflect the difficulties faced by olmutinib and other third generation EGFR inhibitors in competing with Tagrisso, as well as the increasingly crowded and rapidly changing non-small cell lung cancer space.

Commercial Deals

FDA Blocks Chinese Contract Manufacturer's OTC Topical Imports

FDA says in a warning letter that Hangzhou Facecare Cosmetics's response to inspectors' findings following a June inspection was inadequate and the firm's imports in September were ordered detained without physical examination at all US ports.

Dermatology Consumer
See All

Company Information

UsernamePublicRestriction

Register